| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $11,986 | 6 | 100 |
Sells | $0 | 0 | 0 |
| Weisblum Eric | Chief Executive Officer | 6 | $11,986 | 0 | $0 | $11,986 |
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Over the last 12 months, insiders at Silo Pharma, Inc. have bought $11,986 and sold $0 worth of Silo Pharma, Inc. stock.
On average, over the past 5 years, insiders at Silo Pharma, Inc. have bought $14,152 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Weisblum Eric (Chief Executive Officer) — $11,986.
The last purchase of 5,000 shares for transaction amount of $2,075 was made by Weisblum Eric (Chief Executive Officer) on 2025‑12‑15.
| 2025-12-15 | Weisblum Eric | Chief Executive Officer | 5,000 0.0647% | $0.41 | $2,075 | -9.51% | ||
| 2025-11-21 | Weisblum Eric | Chief Executive Officer | 1,000 0.0118% | $0.36 | $365 | -2.75% | ||
| 2025-11-20 | Weisblum Eric | Chief Executive Officer | 1,000 0.0128% | $0.37 | $370 | +4.40% | ||
| 2025-11-19 | Weisblum Eric | Chief Executive Officer | 4,500 0.058% | $0.41 | $1,823 | -3.91% | ||
| 2025-11-18 | Weisblum Eric | Chief Executive Officer | 7,500 0.0924% | $0.40 | $3,025 | -9.40% | ||
| 2025-05-27 | Weisblum Eric | Chief Executive Officer | 10,000 0.135% | $0.43 | $4,329 | +30.58% | ||
| 2024-12-13 | Weisblum Eric | CEO and President | 2,500 0.0557% | $0.84 | $2,097 | -17.12% | ||
| 2024-11-22 | Weisblum Eric | CEO and President | 2,500 0.0502% | $0.90 | $2,250 | -13.79% | ||
| 2024-11-20 | Weisblum Eric | CEO and President | 2,500 0.053% | $0.95 | $2,375 | -21.10% | ||
| 2024-06-12 | Weisblum Eric | CEO and President | 4,438 0.1099% | $1.11 | $4,926 | -0.90% | ||
| 2024-06-11 | Weisblum Eric | CEO and President | 562 0.0135% | $1.08 | $607 | -2.65% | ||
| 2024-04-05 | Weisblum Eric | CEO and President | 400 0.0181% | $2.03 | $812 | -39.02% | ||
| 2024-04-04 | Weisblum Eric | CEO and President | 600 0.0262% | $1.96 | $1,176 | -36.55% | ||
| 2024-04-01 | Weisblum Eric | CEO and President | 1,100 0.0469% | $1.91 | $2,101 | -32.63% | ||
| 2024-03-28 | Weisblum Eric | CEO and President | 3,408 0.1474% | $1.94 | $6,612 | -34.36% | ||
| 2023-12-20 | Weisblum Eric | CEO and President | 200 0.0072% | $1.61 | $322 | -8.39% | ||
| 2023-12-19 | Weisblum Eric | CEO and President | 500 0.0182% | $1.63 | $815 | -10.94% | ||
| 2023-12-15 | Weisblum Eric | CEO and President | 900 0.0305% | $1.52 | $1,368 | -4.64% | ||
| 2023-12-14 | Weisblum Eric | CEO and President | 200 0.0067% | $1.50 | $300 | -4.00% | ||
| 2023-12-07 | Weisblum Eric | CEO and President | 324 0.0098% | $1.36 | $441 | -2.03% |
| Weisblum Eric | Chief Executive Officer | 216932 2.726% | $63,127.21 | 42 | 0 | <0.0001% |
| Ryweck Daniel E. | Chief Financial Officer | 5000 0.0628% | $1,455.00 | 1 | 0 | <0.0001% |
$1,848,072 | 66 | -14.67% | $2.53M | |
$1,138,733 | 28 | -4.94% | $3.28M | |
$8,079,884 | 14 | -43.20% | $1.4M | |
$82,890 | 11 | -16.74% | $1.7M | |
$105,917 | 11 | -28.06% | $2.42M | |
$126,023 | 10 | -66.17% | $2.83M | |
Silo Pharma, Inc. (SILO) | $18,269 | 10 | -21.15% | $2.32M |
$90,087 | 9 | 20.06% | $2.32M | |
$245,000 | 7 | -62.00% | $3.12M | |
$7,268,979 | 7 | -48.44% | $2.54M | |
$70,828 | 6 | -57.96% | $1.59M | |
$553,551 | 4 | -74.30% | $541,204.00 | |
$149,778 | 4 | -45.16% | $3.08M | |
$726,438 | 4 | -72.85% | $1.03M | |
$1,049,630 | 1 | -74.91% | $879,209.00 | |
$9,963 | 1 | -14.25% | $2.47M | |
$23,454 | 1 | -99.16% | $13,279.00 | |
$19,863 | 1 | 144.27% | $1.21M | |
$37,000 | 1 | 79.42% | $2.74M |
| Increased Positions | 9 | +50% | 1M | +307.68% |
| Decreased Positions | 8 | -44.44% | 139,064 | -33.45% |
| New Positions | 5 | New | 1M | New |
| Sold Out Positions | 5 | Sold Out | 109,349 | Sold Out |
| Total Postitions | 19 | +5.56% | 2M | +274.24% |
| Anson Funds Management Lp | $320.00 | 7.33% | 952,381 | +952,381 | New | 2025-09-30 |
| Advisorshares Investments Llc | $123.00 | 2.81% | 364,878 | +180,642 | +98.05% | 2025-09-30 |
| Virtu Financial Llc | $36.00 | 0.83% | 107,786 | +107,786 | New | 2025-09-30 |
| Geode Capital Management, Llc | $13.00 | 0.31% | 39,596 | +289 | +0.73% | 2025-09-30 |
| Jane Street Group, Llc | $6.00 | 0.13% | 16,772 | +16,772 | New | 2025-09-30 |
| Two Sigma Securities, Llc | $6.00 | 0.13% | 16,471 | -26,748 | -61.89% | 2025-09-30 |
| Vanguard Group Inc | $5.00 | 0.13% | 16,334 | 0 | 0% | 2025-09-30 |
| Stonex Group Inc. | $5.00 | 0.1% | 13,430 | +13,430 | New | 2025-09-30 |
| State Street Corp | $4.00 | 0.1% | 12,500 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $3.00 | 0.07% | 8,984 | +8,984 | New | 2025-09-30 |